10-Q: REMSleep Holdings Reports Q3 2024 Results with Increased Development Costs and Ongoing Going Concern Concerns

REMSleep Holdings reported a net loss of $756,088 for the nine months ended September 30, 2024, with increased development expenses and concerns about the company's ability to continue as a going concern.

Summary

• REMSleep Holdings, Inc. reported its financial results for the third quarter of 2024, showing a net loss of $277,909 for the three months ended September 30, 2024, compared to a net loss of $270,433 for the same period in 2023.
• For the nine months ended September 30, 2024, the company's net loss was $756,088, compared to a net loss of $719,890 for the same period in 2023.
• Revenue for the three months ended September 30, 2024, was $37,260, while cost of goods sold was $58,560, indicating sales below cost to liquidate inventory.
• For the nine months ended September 30, 2024, revenue was $122,735 and cost of goods sold was $78,090, showing a decrease in sales compared to the same period in 2023.
• The company's operating expenses increased, particularly in development, which rose to $196,795 for the nine months ended September 30, 2024, due to costs associated with the DeltaWave product's development and FDA approval.
• The company's cash balance was $534,714 as of September 30, 2024, down from $719,100 at the end of 2023.
• The company has an accumulated deficit of $14,948,847 as of September 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including decreased revenue, increased losses, and a going concern issue. While there are some positive developments, such as FDA approval for a new product, the overall sentiment is negative due to the company's financial instability.

Positives

• The company received FDA 510k approval for its DeltaWave product on July 2, 2024.
• The company expects to have DeltaWave product inventory ready for the market in the fourth quarter of 2024.
• The company has a patent for its DeltaWave CPAP Pillows Mask.
• The company has reduced general and administrative expenses by $119,797 for the nine months ended September 30, 2024, compared to the same period in 2023.

Negatives

• The company experienced a net loss of $756,088 for the nine months ended September 30, 2024.
• The company's revenue decreased to $122,735 for the nine months ended September 30, 2024, compared to $196,262 for the same period in 2023.
• The company sold units below cost to liquidate inventory.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has an accumulated deficit of $14,948,847 as of September 30, 2024.
• The company's cash balance decreased to $534,714 as of September 30, 2024.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and the need for additional financing.
• The company's future success depends on its ability to generate capital financing.
• The company faces intense competition in the sleep apnea product market.
• The company needs to develop a sales and marketing infrastructure.
• The company needs to secure reliable sources of raw materials.
• The company needs to acquire or develop a manufacturing capability.
• The company's disclosure controls and procedures were not effective as of September 30, 2024, due to a lack of segregation of duties.

Future Outlook

The company plans to continue to finance its operations through debt and/or equity financing as needed and expects to have product inventory for the DeltaWave ready for the market in the fourth quarter of 2024. The company aims to capture 10% of the market in the next 24 months.

Management Comments

• Management believes that the DeltaWave is designed to effectively address the issues that affect a patient's ability to comply with treatment.
• Management plans to conduct clinical trials to test product effectiveness, pending adequate financing.
• Management is focused on obtaining funding from new investors to alleviate the working capital deficiency and implementing a plan to generate sales.

Industry Context

The company operates in the competitive sleep apnea market, where mask comfort and compliance are key concerns. The company's DeltaWave product is designed to address these issues, but it faces competition from larger, better-capitalized companies. The company's success depends on its ability to commercialize its technology and capture market share.

Comparison to Industry Standards

• The company's revenue of $122,735 for the nine months ended September 30, 2024, is significantly lower than established players in the sleep apnea market, such as ResMed (RMD) and Philips (PHG), which report billions in annual revenue.
• The company's net loss of $756,088 for the nine months ended September 30, 2024, contrasts with the profitability of larger competitors like ResMed, which reported a net income of $595.8 million for the fiscal year ended June 30, 2024.
• The company's development expenses of $196,795 for the nine months ended September 30, 2024, are relatively low compared to the R&D spending of major medical device companies, which can invest hundreds of millions annually.
• The company's cash balance of $534,714 is significantly lower than the cash reserves of larger competitors, which often have billions in cash and equivalents.
• The company's going concern issues are not typical for established medical device companies, which generally have stable financial positions and access to capital markets.

Related Party Transactions

• The company has an employment agreement with Mr. Wood, who is compensated $8,000 per month.
• The company made cash payments to Mr. Lane, the Chief Technology Officer, of $33,000 and $28,000 for the nine months ended September 30, 2024 and 2023, respectively.
• The company paid $22,100 and $13,000 to the brother of the CEO for services related to product development for the nine months ended September 30, 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern issues and financial losses.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers may be affected by the company's ability to deliver products and services.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company plans to obtain funding from new investors to alleviate its working capital deficiency.
• The company plans to implement a plan to generate sales.
• The company expects to have product inventory for the DeltaWave ready for the market in the fourth quarter of 2024.
• The company will continue to finance its operations through debt and/or equity financing as needed.

Key Dates

Keywords

sleep apnea, CPAP, DeltaWave, FDA approval, financial results, going concern, convertible note, equity financing, medical devices, respiratory therapy